Sign Up And Receive Our Latest Promotions!
.svg){kind=small}
Clinics & Hospitals
Healthcare providers rely on data for decisions, but much of the data in clinics and hospitals is decentralized and disparate in nature. Generally, data is on closed systems, inaccessible or unable to aggregate with other data for enterprise-wide insights. This creates operational inefficiencies, gaps to understanding outcomes and identifying the right candidates for clinical studies.
RetinAI Discovery is a CE-Marked medical image and data management platform with certified AI Models to aggregate data an extracting automatic insights on patient diseases and outcomes. The platform can be configured to connect to PACS or integrate via API calls with the clinic systems.
Use cases for Clinics & Hospitals
RetinAI Discovery has been deployed with a major Ophthalmology hospital to aggregate over 100,000 datasets across multiple imaging types.
Ophthalmologists in this setting have a single medical and imaging data platform via Discovery that is secure, cloud-based and provides real-time data access.
RetinAI's AI models can be used to analyze patient-level data to identify biomarkers and automatically segment and quantify fluid and layers in retinal pathologies.
The models have supported identification of subgroups of patients related to disease progression and treatment outcomes, accelerating participation in clinical trials.
RetinAI Discovery is a platform for participative research and management. Users of the platform can easily share cases with other users granted access, anytime from anywhere.
Interested in learning more?
*Disclaimer
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
The AI modules for biomarkers, fluid and layer segmentation and quantification
in retinal pathologies are for research use only in the USA.
The Advanced Segmentation and GA modules are for research use only.
Please be advised these tools are not intended to be a substitute for medical advice, diagnosis or treatment.
We do not warrant any reliance on the accuracy, completeness or usefulness of any content.
